The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Identity and Independence: Many AYAs are in a developmental stage where they are gaining autonomy. A cancer diagnosis can ...

The subcutaneous formulation of daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma.

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

According to a nurse practitioner who works in myeloma research, nurses and APPs are responsible for much of the clinical ...